Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
New research has identified hundreds of proteins that can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, and therefore have treatment potential.
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Medical Journal March 28, 2023
2.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
3.
Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC
4.
FDA Authorizes Three Different Uses for Injectable Antibiotic.
5.
Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.
1.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
2.
The Statistical Evolution of Cancer Staging and Its Precision Impact on Prognosis and Therapy in Cancer Staging 2025
3.
From Birthmarks to Tumors: The Science Behind Infantile Hemangioma
4.
Case Study: The Role of Machine Learning in the Detection of Skin Cancer
5.
Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge